NCT03613844 · Phase 2 · COMPLETED
DHA Brain Delivery Trial
This trial is testing whether APOE4 carriers absorb less DHA (an omega-3 fatty acid) into the brain compared to non-carriers, and whether DHA supplements can close that gap. Researchers are measuring actual DHA levels in the brain, not just in the blood. It is a Phase 2 trial, meaning it is exploring whether the approach works and is safe, not a proven treatment.
You may qualify if
- Age: ≥ 55 and ≤ 80
- At least one dementia risk factor (obesity, education years, hypertension, hyperlipidemia)
- Mini-Mental State Examination (MMSE) ≥ 25
- Logical Memory II delayed recall score ≥ 6 and ≤ 18 .
You're excluded if
- Diagnosis of dementia as assessed by the investigator
- Use of omega-3 preparations in the last 3 months
- > 200 mg/day of DHA consumption using a validated questionnaire
- Use of donepezil, rivastigmine, galantamine and/or memantine
- Alcohol or drug abuse
- A concomitant serious disease such as active cancer treatment or HIV.
- Participation in a clinical trial in the last 30 days
- Use of anticoagulants such as Plavix or Coumadin or the newer generation blood thinners.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-06-07